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Despite extensive research during  the past few years, the mechanism  of lysis 
by  cytolytic T  lymphocytes  (CTL) 1 is  poorly  understood  (1).  Even  less  well 
elucidated is the nature of the antigen-specific T  cell receptor (2,  3).  Although 
both of these activities must be present for a  CTL to specifically recognize and 
lyse a target cell, the cellular requirements for their expression remain obscure. 
Recently, preliminary studies from this laboratory (4) have shown that "cybrids" 
obtained by fusion of enucleated cloned CTL with noncytolytic EL4 cells could 
display specific cytolytic activity.  Although  this activity was low and  somewhat 
variable,  it  seemed to  indicate  that  participation  of the  CTL  nucleus was not 
necessary. 
An alternative approach to investigate the putative role of membrane compo- 
nents in cytolytic activity would be to transfer CTL-derived material  to noncy- 
tolytic recipient  cells via synthetic liposomes.  In this context,  work from Jako- 
bovits et al. (5) demonstrated that T  or B lymphoid cells acquired the ability to 
respond to normally nonstimulatory  mitogens upon fusion with liposomes con- 
taining B or T  lymphocyte membrane components. In other words, B cells fused 
with T  cell membrane components could now respond to concanavalin  A  (Con 
A); likewise, T  cells fused with B cell membrane components could be stimulated 
by  iipopolysaccharide  (LPS).  These  results  indicated  that  the  inability  of  a 
particular  lymphocyte population  to respond  to a  specific mitogen  was due to 
the lack of suitable membrane receptors, but not to an inherent cellular (nuclear) 
defect. 
In the present study, we investigated the requirements  for the expression of 
antigen specificity and cytolytic activity by constructing liposomes composed of 
detergent-solubilized  CTL clones (separated from nuclear constituents),  exoge- 
nous lipids, and Sendal virus envelope proteins, and fusing these liposomes with 
various noncytolytic cell lines.  The  resultant  fusion products were observed to 
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be highly cytolytic and appeared  to exhibit the same specificity as the original 
CTL clone. The process of liposomal transfer was found to be very efficient and 
could be applied to cellular recipients other than  those of T  cell origin. These 
experiments  demonstrated  operationally  that  both  the  antigen-specific  T  cell 
receptor and  the  CTL lytic machinery could be solubilized and  transferred  to 
recipients that did not display these properties. 
Materials and Methods 
Reagents.  Dipalmitoylphosphatidylcholine (DPPC)  (98%  pure)  was  obtained  from 
Sigma Chemical Co., St. Louis, MO and stored as a stock solution in chloroform (Merck 
Sharp & Dohme AG, Zurich, Switzerland) and  100 mg/ml under nitrogen. Cholesterol 
(99% pure; Calbiochem-Behring Corp., La Jolla, CA) was stored at 50 mg/ml in chloro- 
form under nitrogen. Both reagents were used without further purification. Con A and 
EGTA were from Pharmacia Fine Chemicals, Uppsala, Sweden and Sigma Chemical Co., 
respectively. Radiolabeled chromium (51Cr) was obtained from IRE, Fleurus, Belgium as 
sodium chromate with a specific activity of 1 mCi/ml. 
Mice.  Adult DBA/2 (H-2d), C57BL/6 (H-2b), and BALB/c (H-2  d) mice were obtained 
from the mouse colony  at the Swiss Institute for Experimental Cancer Research, Epalinges, 
Switzerland. The original breeding pairs were obtained from The Jackson Laboratory, 
Bar Harbor, ME. 
Interleukin 2 (IL-2) Source.  Supernatants collected from a subline of EL4 thymoma cells 
(kindly provided by J. Farrar, Bethesda, MD) that were stimulated (108 cells/ml) for 40 h 
in the presence of 10 ng/ml phorbol-12-myristate-13-acetate (6) were used as a standard 
source of IL-2. 
Virus Stocks.  Sendai virus (original stocks were generously donated by Dr. L.  Roux, 
Geneva, Switzerland) was grown in LLC-MK2 cells or in 10-d-old embryonated chicken 
eggs as described by Scheid and Choppin (7) and Roux and Holland (8). 
Cell Lines.  The following tumor cell lines were used: P815 (H-2  a,  DBA/2 mastocy- 
toma), EL4 (H-2  b, thymoma), BW5147 (H-2  k, thymoma of AKR origin), M12.4.1 (H-2  d, 
B cell lymphoma of BALB/c origin), LSTRA (H-2  d, a Moloney leukemia virus (MoLV)- 
transformed line of BALB/c origin), and  MBL-2  (H-2  b,  a  MoLV-transformed line of 
C57BL/6 origin). All cell lines were maintained in vitro except for LSTRA and MBL-2, 
which were passaged (weekly) in vivo in their respective strains of origin. 
CTL Clones.  CTL clones used in these experiments were derived by micromanipulation 
as described in detail elsewhere (9,  10). Briefly, populations enriched in antigen-specific 
cells were obtained by immunization in vivo and/or in vitro with allogeneic or MoLV- 
transformed tumor cells.  These populations were cloned in the presence of irradiated, 
antigenically relevant cells together with a source of IL-2. For routine maintenance, the 
clones were passaged once weekly by plating 5 ×  105-1  ×  10  6 cloned cells together with 
irradiated feeder cells and/or antigen in 40 ml of Dulbecco's modified Eagle's medium 
(DMEM) supplemented with  5%  heat-inactivated fetal bovine serum  (FBS)  (Seromed, 
Munich, Federal Republic of Germany [FRG]), 5 ×  10  -~ M 2-mercaptoethanol, 10 mM 
Hepes, penicillin/streptomycin, additional amino acids (11), and a source of IL-2 in 150- 
mm petri dishes. Clones A9 and B3 were derived from 5-d primary BALB/c anti-DBA/2 
mixed lymphocyte cultures. Both of these clones are anti-Mlsa-specific,  noncytolytic, and 
have been described elsewhere (12).  CTL clones 7,  10,  11, and  12 were derived from 
peritoneal exudate lymphocytes isolated from C57BL/6 mice immunized against P815 
cells.  Clone  11  has a  known specificity of anti-H-2K  a (data not shown). Clone  14 is a 
C57BL/6-derived CTL clone directed against MoLV-associated antigenic determinants. 
Cytolytic Assay.  Effector cells and 5'Cr-labeled target cells (generally 8,000/well) were 
mixed at various effector/target (E/T) ratios in round-bottom, 96-well  microtiter plates 
(Greiner, Nurtingen, FRG), centrifuged (1,000 rpm, 2 min), and incubated at 37°C for 2 
h as previously described (11).  At this time, the plates were centrifuged (2,000 rpm,  5 
rain), the supernatant of each well  was collected, and the radioactivity measured in  a 
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bated in medium alone or in  1%  Nonidet  P-40 (NP-40) detergent  were used to obtain 
spontaneous and  maximum 5~Cr-release  values, respectively.  Percent  specific lysis was 
calculated as described (11).  All E/T data points were performed in replicates of three to 
six with the standard deviation of any series of replicates not >12%. 
For assays in  which  lectin  was present,  Con  A  was added  to the effector/target cell 
mixtures at 5 #g/ml and remained in the assay for its duration. During the cytolytic assays 
in which EGTA was used, effector and target cells were mixed, centrifuged as described 
above, and incubated for 30 rain at 23°C.  EGTA (20 raM/well final concentration) was 
then added and the cells incubated an additional 2 h at 37°C before determination of the 
5~Cr-release.  In  the  antibody-blocking experiments,  target  cells,  monoclonal  antibody 
(mAb) (1:500  final dilution),  and effector cells were added in that order, and the assay 
performed as described above, mAb was present throughout the course of the assay. The 
mAb used (S13-I 1, anti-H-2K  a) was the kind gift of Dr. S. Tonkonogy, North Carolina 
State University, Raleigh, NC. 
Preparation of Liposomes.  Liposomes were prepared by a  modification  of previously 
published procedures (13-15). Briefly, donor cells were extensively washed in phosphate- 
buffered saline (PBS) to remove medium and serum contaminants, followed by a 30 min 
incubation at 4°C in 0.5% NP-40-Tris-HCl-saline buffer, pH 7.4. After centrifugation at 
3,000 rpm for 10 min (to remove nuclei and mitochondria), the supernate was collected 
and added  to Sendai  virus hemagglutinin/neuraminidase  (HN) and fusion (F) proteins 
that had been prepared as described (7). The cellular/viral protein mixture (ratio of 5- 
10:1)  was then  added  to lipids  (DPPC  and  cholesterol,  1:1  molar ratios;  protein/lipid 
ratio,  1:1) previously dried from chloroform by nitrogen in a small, round-bottom flask 
and incubated for 5 min at 37°C. The flask was vortexed briefly and the solution dialyzed 
against a  1,000-fold excess of PBS at 4°C  for 48 h.  In a  typical experiment, 50  ×  106 
donor  cells  were  solubilized  in  1.0  ml  of detergent-containing  buffer,  resulting  in  a 
supernate containing ~ 1 mg of cellular protein. This material was then added to 100 #g 
of purified HN and F proteins (in  1.0  ml), and the cellular/viral protein mixture added 
to  1.1  mg of dried  lipids (DPPC and cholesterol,  1:1  molar ratio). The 2.0 ml solution 
was dialyzed against 2 liters of PBS.  At the end of 48 h, the liposomes were collected by 
high-speed centrifugation  (50,000  g,  1 h)  and  washed with  PBS  in  this  manner.  The 
resuspended liposomal pellet would then be defined as containing 50 ×  108 cell equivalents. 
This method resulted in  the formation of multilamellar liposomes ranging in size  from 
0.5 to 10 #m, with the majority in the 1-4 #m range. Approximately 50% of the original 
cellular protein is incorporated into the liposomes. 
Cellular Reconstructions.  Liposomes and recipient cells were incubated together in  1.0 
ml of 0.14 M NaC1,  I0 mM Tris-HCl, 3 mM KCI, 0.8 mM MgSO4, pH 7.4, buffer for 60 
rain at 4°C to allow liposome/cell binding. The cells were washed by centrifugation (1,500 
rpm, 5  min, twice) in ice-cold PBS and resuspended in  1.0  mi of DMEM without FBS. 
The cells were then incubated for 30 min at 37 °C to allow liposome/cell fusion, washed 
twice by centrifugation in  DMEM containing FBS,  and resuspended in DMEM-FBS for 
the  assays.  Unless  otherwise stated,  all  fusions  were  performed at a  ratio  of two cell 
equivalents of liposomes to recipient cells; i.e., in a typical experiment 1 ×  106 recipient 
cells  were  fused  with  liposomes derived  from the  equivalent  of 2  ×  106  donor cells. 
Designation  of the  experimental protocol  is  "F(donor)/recipient",  which  indicates  that 
liposomes derived from a specific donor were fused to the indicated recipient. 
Results 
Characterization of the Transfer  System.  The experimental  procedure  we used 
to examine the requirements  for the expression of cytolytic activity and immu- 
nologic specificity by CTL consisted of the following steps. Cytolytic T  cell clones 
were  solubilized  in  the  nonionic  detergent  NP-40  and  the  matrix  and  plasma 
membrane components separated from nuclear and mitochondrial constituents. 
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retained to increase liposome stability (14). To this cellular protein mixture were 
added Sendai virus envelope proteins that  had been purified from detergent- 
solubilized  viral  preparations.  These  envelope proteins  were of two  types:  a 
hemagglutinin-neuraminidase protein (HN) and a fusion protein (F). The HN is 
required  for  virus  binding  to  cells,  while  F  mediates  the  fusion  of viral/cell 
membranes. The viral/cellular protein mixture was added to exogenous lipids 
to construct liposomes.  Exogenous lipids were included to reduce the require- 
ments for large amounts of cloned CTL cells and Sendal virus, whose natural 
iipids would otherwise be the only source of lipids for liposome construction. 
Liposomes were formed by dialysis of the lipid-protein mixture against PBS and 
harvested  by  high  speed  centrifugation.  This  procedure  yielded  only  large 
multilameilar liposomes,  the average size  being  -1-4  #m.  To  fuse liposomes 
with recipient cells, we incubated the two together at 4°C for 60 min to allow 
Sendal HN protein-mediated binding of liposomes to the cells. The cells were 
then  pelleted  by  centrifugation,  resuspended  in  medium  without  FBS,  and 
incubated at 37°C for 30 min to allow F protein-mediated fusion of the bound 
liposomes with  the cells.  At  the  end of this  time,  the  fused cells  were again 
pelleted and washed by centrifugation. The fused cells were then used immedi- 
ately in assays to test for cytolytic activity and immunologic specificity. 
When liposomes were derived in this manner from C57BL/6 anti-P815 CTL 
clones and fused with  noncytolytic anti-Mls  ~ T  cell clones., it was found that 
specific cytolytic activity could be transferred to cells that lacked this property 
(Table I). The presence of this activity in the fusion products was evidenced by 
the ability of the cells to lyse P815 target cells but not the irrelevant EL4 target 
cells. The reconstruction of cytolytic cells seemed to be possible using liposomes 
prepared from a single CTL clone or a mixture of several C57BL/6 anti-P815 
TABLE  I 
Transfer of Cytolytic Activity by Liposomes to Noncytolytic  T Cell Clones 
Experiment  Effector population 
Percent specific lysis* 
P815  EL4 
(H-2  d)  (H-2  b) 
1'  Liposomes alone  0  9  0 
Clone A9 alone  8  0 
F(7)/A9  65  7 
2 i  Liposomes alone  a  6  0 
Clone A9 alone  5  0 
Clone B3 alone  6  0 
F(7,10,11,12)/A9  72  0 
F(7,10,11,12)/B3  67  0 
* Data  are  expressed  as  the  percent  specific  lysis  obtained  after  2-h 
incubation at an E/T cell ratio of 10:1. 
* Liposomes were derived from CTL clone 7  (C57BL/6 anti-P815) and 
fused with noncytolytic clone A9 (anti-Mlsa). 
0 Equivalent number of liposomes were used as would be present in the 
fusion products. 
! Liposomes were derived from a mixture of CTL clones 7,10,I 1, and 12 
(all C57BL/6 anti-P815) and fused with either clone A9 or clone B3, 
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TABLE  II 
Acquisition of Specific Cytolytic Activity by Noncytolytic Clones Requires 
Fusion of Liposomes Derived from Cytolytic Clones with Intact Cells 
Percent specific lysis 
Experiment  Effector population  P815  EL4 
(H-2 d)  (H-2  b) 
1"  Clone A9 alone  5  ND* 
Clone A9 + Con A  5  ND 
Liposomes alone  2  ND 
Liposomes + Con A  2  ND 
F( 10)/A9  8 8  1 
2 o 
31 
Clone A9 alone  3  0 
EL4 alone  0  0 
Liposomes (7) alone  1  0 
Liposomes (EL4) alone  1  1 
Clone 7  97  6 
F(EL4)]7  91  0 
F(EL4)/A9  1  0 
F(7)/A9  85  0 
Clone A9 alone  1  ND 
Clone 10  56  ND 
F(10)/A9  65  ND 
Clone I0 + EGTA  0  ND 
F(10)/A9 + EGTA  1  ND 
Experiments 1, 2, and 3 represent three independent experiments. 
* Liposomes were derived from CTL clone 10 (C57BL/6 anti-PSI5) and 
fused with noncytolytic clone A9 (anti-Mls'). Cytotoxicity assays were 
performed at an  E/T  cell ratio of 10:1 for 2  h  at  37°C.  Whenever 
indicated, Con A (5 #g/ml) was present throughout the assay. 
* Not done. 
! Liposomes were derived from either CTL clone 7 (C57BL/6 anti-P815) 
or EL4 tumor cell line and fused with either clone 7 or clone A9. S~Cr- 
release assays were performed at an E]T cell ratio of 10:1. 
! Liposomes were derived from clone I 0 (C57BL/6 anti-P815) and fused 
with clone A9. Cytotoxicity assays were performed at an E/T cell ratio 
of 1  : 1. Whenever indicated, the effector and target cells were incubated 
at 23 °C for 30 rain, EGTA was added (20 raM/well final concentration), 
and the cells incubated for an additional 2 h at 37°C. 
CTL  clones. 
In  additional experiments,  we determined  that  neither  the  constructed  lipo- 
somes nor  the  recipient cells were able to induce  cytolysis when  the lectin Con 
A  was  included  in  the  cytolytic assay  (Table  II,  experiment  1).  Cytolysis was 
observed only when  the  liposomes had been  fused with the recipient cells. This 
observation excluded the possibility that iysis of the target cells was the result of 
unfused  liposomes  present  in  the  assay  or  a  latent  cytolytic  capacity  of  the 
recipient cells.  This  experiment  also showed  that  the  iiposomes by themselves 
were not toxic to the target cells. 
It is possible, however,  that the cytolytic activity could be due  to a  functional 
alteration in  the recipient cells as a  result of the  fusion  such  that  the antigenic 
specificity would be contributed  by the donor  liposomes and the cytolysis by the 266  TRANSFER  OF  SPECIFIC  CYTOLYTIC  ACTIVITY  BY  LIPOSOMES 
recipient  cells.  To  examine this  possibility,  liposomes were constructed from 
either  cytolytic or  noncytolytic cell  lines  and  fused  with  either  cytolytic or 
noncytolytic recipients (Table II, experiment 2).  When liposomes from a  non- 
cytolytic T  cell line (EL4) were fused with a cytolytic CTL clone, the fused clone 
was unaltered in its cytolytic capacity. When the liposomes from noncytolytic T 
cells  were  fused  with  noncytolytic recipients,  the  fusion  products  remained 
noncytolytic. Only when the liposomes were derived from cytolytic donors were 
cytolytic fusion products obtained. Thus, it appears that to obtain cytolytic fusion 
products, the donor cells must be cytolytic and the liposomes must be introduced 
into cells. 
We also examined the effect of EGTA on the cytolytic activity displayed by 
the fusion products (Table II, experiment 3). It has been previously demonstrated 
(16) that Mg  ~+ is required for CTL binding to target ceils, while Ca 2+ is essential 
for the cytolytic phase of the lyric process. The cytolytic assay was performed as 
usual except that a  30 min preincubation period at 23°C was included. Under 
these conditions, the fusion products bound to the target cells (as observed by 
light microscopy) but lysis was negligible. The mixture of fusion products and 
target cells was  then incubated for 2  h  at  37°C in the presence or absence of 
EGTA, which chelates Ca  2+. The fusion products behaved exactly as the CTL 
clone from which the liposomes had been derived. That is, cytolysis was com- 
pletely inhibited when Ca  2+ was not available in the assay. 
In  the  experiments  described  above,  the  cytolytic  capacity  of the  fusion 
products  was  examined at  only one E/T  ratio.  Additional  experiments were 
performed in which the lytic capacity of the fusion products was compared with 
that of the donor CTL clones. The results of a  representative experiment are 
shown in Fig.  I. It can be seen that over a wide range of E/T ratios (1:3-10:1), 
the lytic activity of the fusion products was similar to that of the donor CTL 
clone.  It  thus appears  that  upon  transfer of components from a  CTL  into  a 
suitable recipient cell (such as A9 or B3), the cytolytic capacity of such a fusion 
product is highly efficient. 
In an attempt to quantitate the liposomai transfer of cellular constituents to 
the various recipient cells, we performed the following experiment. Viable donor 
CTL  were labeled  with  fluorescein isothiocyanate (FITC)  (17)  and  liposomes 
constructed as described above.  These  liposomes were then  fused to  various 
recipient cells and examined for fluorescence by fluorescence-activated  cell sorter 
(FACS) analysis.  Positive controls consisted of donor cells freshly labeled with 
FITC.  Negative  controls  were  recipient  cells  incubated  with  identically con- 
structed liposomes lacking the Sendai virus HN and F proteins. Examination of 
three different recipient cells demonstrated that  indeed transfer of FITC  had 
occurred during the fusion process. It was observed that  100% of the recipient 
cells (for each of the three different cell types) had undergone fusion as assessed 
by this criterion. Calculation of the amount of fluorescent material transferred 
revealed that each of the recipient cell types examined had acquired ~5% of the 
labeled cellular components present in the positive controls (data not shown). 
Antige~ic Specificity of Fusion Products.  To further verify the specificity of the 
/ytic activity of the fusion products, we derived liposomes from a  C57BL/6 (H- 
2 b) anti-P815  CTL clone directed against H-2K  a alloantigens (that is,  its lytic HARRIS,  MACDONALD,  AND  CEROTTINI  267 
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FIGURE  1.  Cytolytic efficiency of fusion product. The CTL donor clone 10 (C57BL/6 anti- 
P815) (O) and the fusion product F(10)/A9 (liposomes constructed from clone 10 and fused 
with clone A9) (e) were assayed for cytolytic activity on P815 target cells in a 2-h, 51Cr-release 
assay. Incubation with liposomes or clone A9 alone resulted in <3% lysis of P815 target cells. 
activity was inhibited by mAb against H-2K  a but not mAb against H-2D  a or H- 
2La), fused them with (anti-MIs  a) noncytolytic clone A9, and then tested whether 
the lytic activity of the fusion products could be blocked by anti-H-2K a  mAb 
(Fig. 2).  It was found that the lytic activity of the fusion products could indeed 
be inhibited by this mAb, indicating that the liposomai transfer had conferred 
to A9 cells the immunologic specificity of the donor CTL. 
The antigenic specificity of the fusion products also was assessed by using a 
panel of target cells bearing different antigens. For these experiments we used 
as liposome donors two C57BL/6 CTL clones with distinct antigenic specificities, 
namely anti-P815 clone 7 and anti-MoLV clone 14. As shown in Fig. 3, clone 7 
displayed lytic activity against P815 (H-2 a) target cells and another H-2 a (MoLV- 
induced)  cell  line,  LSTRA.  However,  it  was  nonreactive  with  H-2 b (MoLV- 
induced) MBL-2 target cells. In contrast, clone 14 lysed MBL-2 target cells but 
had no activity against P815  or LSTRA tumor cells.  When liposomes derived 268  TRANSFER  OF  SPECIFIC  CYTOLYTIC  ACTIVITY  BY  LIPOSOMES 
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FIGURE 2.  Ability of monoclonal antibody  to  inhibit the  acquired  lytic activity of fusion 
products.  Cytolytic assays  were performed either in the presence (solid symbols) or absence 
d  51  (open symbols) of mAb S 13-11  (anti-H-2K).  Cr-labeled PS15 cells were used as target cells 
and either clone  11  (C57BL/6 anti-H-2K  d) or the fusion product  F(11)]A9 (liposomes con- 
structed from clone 11 and fused with clone A9) were used as effector cells. 
from clone 7 were fused with A9 cells, the fusion products exhibited the same 
specificity pattern as CTL clone 7 (Fig. 3). Reciprocally, when clone 14 was used 
as the liposome donor, the fusion products obtained with A9 cells exhibited the 
same lytic reactivity as CTL clone 14. These results thus indicate that immuno- 
logical specificity was related to the source of liposomes and not to the recipient 
cells. 
Dose-Response Analysis  of Liposomal  Transfer.  To  examine  the  efficiency of 
liposomal transfer, varying numbers of liposomes from clone 7 or clone 14 were 
fused with the noncytolytic clone A9, and the lytic activity of the fusion products 
was tested on the corresponding target cells. The results of two such experiments 
are  shown  in  Fig.  4.  It  can  be  seen  that  the  solubilization  of the  CTL  and 
subsequent liposomal transfer to the recipient cells was a highly efficient process, 
since significant cytolytic activity was imparted to the A9 recipient cells after 
fusion with one cell equivalent of liposomes from either CTL clone. In these 
experiments, maximal efficiency of transfer occurred with five cell equivalents 
of liposomes.  In  other  experiments,  transfer  of two  to  five  cell  equivalents 
resulted  in  comparable  lytic  activity.  Surprisingly,  a  further  increase  in  the 
amount  of liposomes  used  for  fusion  resulted  in  a  concomitant decrease  in 
cytolytic activity. Further experiments in which unfused liposomes were titrated 
into  a  cytolytic assay demonstrated that  such free liposomes did  not directly 
inhibit cytolysis (data not shown). Whether this decrease of activity was due to 
the introduction of excess lipids and/or cellular proteins has not been ascertained, 
but recipient cell viability was equivalent at all cell equivalent ratios tested (>90%; 
data not shown). 
Liposomal  Transfer  of Cytolytic Activity  Is  Not  Restricted  to  Noncytolytic  T  Cell HARRIS,  MACDONALD, AND  CEROTTINI  269 
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FIGURE 3.  Specificity of fusion products. Liposomes were constructed from either clone 7 
(C57BL/6 anti-P815) or clone 14 (C57BL/6 anti-MoLV) and fused with clone A9 (anti-Mls~). 
The original CTL clones and the fusion products were assayed for cytolytic activity in a 2-h, 
51Cr-release assay. Target cells were either P815 (H-2d), LSTRA (H-2n-MoLV),  or MBL-2  (H- 
2b-MoLV). Effector populations consisted of clone 7 (O), clone 14 (A), F(7)/A9 (O), and F(14)/ 
A9 (&). Lysis  of any one of the target cells by either of the liposome populations or clone A9 
alone was <2% at an E/T cell ratio of 10:I. Experiments 1 and 2 represent two independent 
experiments. 
Clones.  In the previous experiments, we had only investigated the possibility of 
transferring the cytolytic activity and/or the antigen specificity from CTL clones 
to noncytolytic T  cell clones. The feasibility of using transformed T  cell lines as 
well as non-T cell lines as recipients for liposomal fusion was also examined. As 
shown  in  Table  III,  it  was  possible  to obtain  cytolytic fusion  products  with  a 
variety of recipient  cells,  although  a  variable  degree  of cytolytic activity  was 
observed. Fusion products obtained with two T  cell lines, the BW5147 thymoma 
and  a  subline  of EL4  thymoma  cells,  expressed  low  but  significant  cytolytic 
activity. However, a  separate subline  of EL4 cells yielded fusion products that 
expressed high cytolytic activity. Surprisingly, fusion products obtained with the 
B  cell line M 12.4.1  were also able to express lytic activity, thus indicating that 270  TRANSFER  OF  SPECIFIC  CYTOLYTIC  ACTIVITY  BY  LIPOSOMES 
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FIOURE 4.  Efficiency of cytolytic transfer between CTL and noncytolytic cells by liposomes. 
Liposornes were constructed and fused with recipient cells at the indicated cell equivalents as 
described in Materials and Methods. 5tCr-release assays  were then performed at an E/T cell 
ratio of 1:I  using either P815  or MBL-2 target cells. (O) clone 7 (C57BL/6-anti-P815);  (0) 
F(7)/A9; (A) clone 14 (C57BL/6 anti-MoLV); (&) F(14)/A9. 
cells other than those of T  cell origin could serve as suitable recipient cells.  In 
these experiments, the clones A9 and  B3,  normally used as recipients in  the 
experiments described above,  again  demonstrated high cytolytic activity after 
fusion  with  the  same  liposomes.  Since  liposome-mediated transfer  of FITC- 
labeled material to each of three different recipients was equivalent (see above), 
these observations suggest that the differences in cytolytic expression among the 
fusion products were not due to different extents of liposomal fusion and transfer 
to the recipient cells, but rather were related to some inherent factor(s) in the 
recipient cells.  Moreover,  it  is  also apparent  that  the cytolytic activity of the 
fusion products was specific irrespective of the origin of the recipient cell, since 
no  lysis  of irrelevant  EL4  target  cells  was  observed  with  any  of the  fusion 
products tested (Table III). 
Discussion 
In this study, we investigated some of the requirements for the expression of 
specific CTL activity by transferring this activity from cloned CTL to various 
noncytolytic recipient  cells.  In  particular,  material  derived  from  detergent- 
solubilized CTL clones was inserted into synthetic liposomes and, with the aid of 
Sendai virus envelope proteins, fused with various recipient cells. These experi- HARRIS,  MACDONALD,  AND  CEROTTINI  271 
TABLE  III 
Liposomal Transfer of Specific Cytolytic Activity  from Cytolytic Clones Is 
Not Restricted to Noncflolytic T Cell Clones 
Experiment  Effector population 
Percent specific lysis* 
P815  EL4 
(H-2  a)  (H-2  b) 
Clone A9 alone  1  ND 
M12.4.1  alone  0  ND 
BW5147 alone  2  ND 
EL4 alone  0  ND 
F(10)/A9'  94  ND 
F(10)/M 12.4.1  62  ND 
F(10)/BW5147  18  ND 
F(10)/EL4. I  17  ND 
2~  Clone A9 alone  3  0 
Clone B3 alone  1  0 
M12.4.1  alone  1  0 
EL4.2 alone  0  0 
F(7)/A91  85  0 
F(7)/B3  70  2 
F(7)/M 12.4.1  77  0 
F(7)/EL4.2  80  0 
* Data are presented as percent specific lysis at an E/T cell ratio of 10:1 
during a 2-h assay. ND, not done. 
* Liposomes were derived from CTL clone 10 (C57BL/6 anti-P815) and 
fused with either noncytolytic clone A9, B cell line M12.4.1, T cell line 
BW5147, or T  cell line EL4.1  (a ouabain-thioguanine-resistant subline 
of EL4). 
Liposomes were derived from CTL clone 7 (C57BL/6 anti-P815) and 
fused with either clone A9, clone B3, B cell line M12.4.1, or T cell line 
EL4.2 (a H-2K  ~- D  b+ subline of EL4). 
! Liposomes derived from either clone 7 or clone  10 resulted  in <3% 
specific lysis when tested alone against either P815 or EL4 target cells. 
ments demonstrated  that both specificity and  lytic activity could be imparted  to 
recipient cells.  Eiposomes constructed  without Sendal virus proteins did not bind 
efficiently  to  recipient  cells and  were  unable  to  transfer  cytolytic  acivity.  Lipo- 
somes containing  both cellular and viral proteins had no direct lyric activity even 
in the presence of Con A. Furthermore,  only when liposomes were derived from 
cytolytic  donors  and  integrated  into  intact  cells  was  specific  cytolytic  activity 
expressed. 
Noncytolytic  T  cell  clones  were  highly  suitable  as  recipient  cells  for  the 
introduction  of specific CTL  components.  Also suitable were various noncytolytic 
tumor  T  cell  lines such  as EL4 and  BW5147.  Although  the  expression  of CTL 
activity varied among  the fusion products obtained with these different recipient 
cells,  each one of the  three  lines  tested  displayed  significant  cytolytic capability. 
It does not seem that this variability in cytolytic expression  was due to the ability 
of the different cell types to be fused with the liposomes.  Possibly, this difference 
is related  to undetermined  nuclear/cytoplasmic  factors.  If some sort of recipient 
cell contribution  is required  for the expression of cytolytic activity after liposomal 272  TRANSFER  OF  SPECIFIC  CYTOLYTIC  ACTIVITY  BY  LIPOSOMES 
fusion (since  iiposomes containing CTL components are themselves inactive), 
then  it  is  reasonable to  expect that  various recipient cell  types could exhibit 
different levels of cytolytic capacity. This contribution could be either nuclear, 
such as a signal from the fusion product to the target cell as proposed by some 
investigators for the mechanism of CTL-mediated lysis (18-20), or could merely 
be a cytoplasmic interaction that, upon receptor occupancy, exposes an enzyme- 
like activity that causes target cell lysis (21, 22). However, it should be noted that 
regardless of the cell type used as a  recipient, there was no difference in the 
antigenic specificity exhibited by the fusion products. Surprisingly, even a lymph- 
oid cell line of non-T cell origin, the B cell line M12.4.1, could serve as a suitable 
functional recipient  for liposomes containing CTL  components.  This  finding 
suggests that metabolic activities necessary for the expression of CTL function 
are present  in  B  cells  but  that  these  cells  lack  the  membrane and/or  other 
cytoplasmic components that are essential for binding to, and/or lysis of target 
cells. Examination of recipient cells other than those of lymphoid origin for their 
ability to express CTL function upon fusion with liposomes is currently under- 
way. If indeed nonlymphoid cells are suitable recipients, the implication would 
be that all cells are potentially able to express such a specialized function, given 
the proper CTL-derived components. 
Experiments involving the ability of mAb to inhibit specifically the lytic activity 
of fusion  products,  as  well  as  the  analysis  of the  patterns  of iytic  reactivity 
displayed by recipient cells of liposomes containing membrane proteins  from 
CTL  of two  different  specificities  confirmed  the  high  degree  of specificity 
conferred by this transfer system. Since no attempt was made to separate the 
function of target cell recognition from that of lysis, it remains to be determined 
whether these two activities can be dissociated or not. 
In contrast to the high cytolytic activity of liposome-derived fusion products 
described here, previous work from our laboratory (4) indicated that cytolytic 
"cybrids" obtained by fusing enucleated CTL clones (which were noncytolytic) 
with EL4 tumor cells expressed low and variable lytic activity. The discrepancy 
may in part be due to the fact that the lytic activity of the CTL clones used in 
the latter experiments was susceptible to inhibition by mAb against Lyt-2 (Lyt- 
2-dependent CTL), while Lyt-2-independent CTL clones were used as liposome 
donors  in  the  experiments presented  here.  CTL  that  are  inhibited  in  their 
activity by anti-Lyt-2 antibodies appear to possess relatively low affinity and/or 
few antigen receptors (23,  24).  Further work is needed, however, to ascertain 
whether the effectiveness of liposome-mediated transfer of CTL activity depends 
on the availability of CTL with high affinity or more numerous receptors. It also 
is noteworthy that enucleated CTL clones were not cytolytic even in the presence 
of Con  A,  but  had  to  be  fused  with  noncytolytic recipient  cells  to  exhibit 
functional activity (4). These findings, which are in agreement with the present 
results, support the contention that the noncytolytic recipient cell provides some 
(nuclear and/or cytoplasmic) contribution that is essential for the expression of 
specific cytolytic activity by fusion products. 
Jakobovits et al.  (5) have demonstrated that the unresponsiveness of lympho- 
cyte populations to particular mitogens was not due to an inherent lack of the 
necessary intracellular machinery, but rather was due to the absence of appro- HARRIS, MACDONALD, AND CEROTTINI  273 
priate membrane components. Upon transfer of B cell membrane components 
to  T  cells,  or  vice  versa,  the  fused  cells  could  now  respond  to  a  normally 
nonstimulatory mitogen. Our ability to construct cytolytic cells using a B cell line 
as a fusion recipient is in accord with these observations. It should be noted that 
the transfer system we used here is similar to that used by Jakobovits et al. (5), 
in  that  we  also  used  Sendal  virus envelope proteins  to  mediate fusion.  This 
system appears to be preferable to that using polyethyleneglycol  because it is less 
toxic (>90% cell viability after fusion) and highly efficient (90-100% of cells can 
be fused). However, our system differs from that ofJakobovits et al. (5) in that 
our liposomes were constructed from synthetic lipids, thus enabling the use of 
smaller quantities of cellular and viral components. 
Finally, although the participation of cytoplasmic CTL constituents (including 
granules) cannot be ruled out,  the present study provides suggestive evidence 
that the cellular component(s) responsible for specific CTL activity resides solely 
in (or is associated with) the plasma membrane and can be fully functional after 
transfer into recipient cells that lack this property.  It is not known, however, 
whether other activities  that  are  linked  with  membrane-associated receptors, 
such as antigen-dependent lymphokine production and cellular proliferation, can 
be expressed by fusion products. If antigen-specific function in fusion products 
can  be  shown  to  be  maintained  for  sufficiently long  periods  of time  (and 
preliminary experiments indicate that near optimal cytolytic activity persists for 
at least 6 h), then the iiposomal transfer system described here should provide a 
powerful tool to examine these questions. Moreover, it may allow a direct testing 
of the functional activity of purified membrane constituents such as the putative 
T  cell receptors recently described by several groups (25-27). 
Summary 
Murine cytolytic T  iymphocytes (CTL) clones were solubilized in Nonidet P- 
40 detergent, and the matrix and membrane proteins separated from the nuclear 
constituents. These proteins, in combination with exogenous lipids and Sendal 
virus envelope proteins, were used to construct liposomes that were then fused 
with noncytolytic cloned T  cell recipients. The resultant fusion products were 
found to be highly cytolytic and appeared to express the same specificity as the 
original donor clone. Further analysis showed that the liposomal transfer process 
was  extremely efficient.  Moreover,  in  addition  to  noncytolytic T  cell  clones, 
three transformed T  cell lines and one B cell line were found to express specific 
cytolytic activity after fusion with appropriate liposomes. Inhibition experiments 
using monoclonal antibodies against target cell antigens, as well as analysis of the 
lytic reactivity pattern  of the  fusion  products,  confirmed the high  degree of 
specificity conferred to the recipient cells. This study thus indicates that the two 
characteristics typically associated with CTL, namely antigen-specific recognition 
and cytolytic activity, can be solubilized from CTL and transferred to recipient 
cells that do not express these characteristics. 
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